The Potential Role of MicroRNAs in Cardiac Myxoma: A comprehensive Review on the Current Evidence
نویسندگان
1 Student Research Committee, School of Medicine, Kerman University of Medical Sciences, Kerman, Iran.
2 Student Research Committee, School of Medicine, Kerman University of Medical Sciences, Kerman, Iran.
3 Student Research Committee, School of Medicine, Kerman University of Medical Sciences, Kerman, Iran.
doi
10.22038/jctm.2025.89910.1499چکیده
Cardiac myxoma (CM) is the most common primary cardiac tumor, often benign but potentially life-threatening due to embolic events and intra-cardiac obstruction. Recent advances suggest a significant role for microRNAs (miRNAs) in CM pathogenesis, diagnosis, and treatment. This review aims to synthesize current evidence regarding the diagnostic implications of miRNAs in cardiac myxoma. Several miRNAs, including miR-217, miR-218, miR-335, miR-320a, miR-122, and miR-634, have been implicated in regulating proliferation, apoptosis, inflammation, and differentiation in CM. Notably, miR-217 and miR-218 act as tumor suppressors, while dysregulated pathways involving Myocyte Enhancer Factor 2D (MEF2D) and Interleukin-6 (IL-6) further elucidate the molecular basis of tumor progression. Circulating miRNA profiles also offer potential as non-invasive diagnostic biomarkers. miRNAs offer promising avenues for both early detection and targeted therapy in cardiac myxoma. Further research into miRNA-based diagnostics and therapeutics may enhance personalized treatment and reduce recurrence risk in affected patients.
